← Back to all signals
RESEARCH PAPER ANALYSIS

Differential Effects of Lifestyle Indicators on Cognitive Functioning Across Healthy, Dementia, Parkinson's Disease, and Stroke Groups.

Large cross-sectional analysis of 17,105 older adults across 27 countries showing that physical inactivity, social participation, and intellectual activities have differential associations with specific cognitive domains across healthy, dementia, Parkinson's disease, and stroke groups, with…

PMID41976920
JournalJournal of clinical medicine
Publication Date2026-03-30
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

Large cross-sectional analysis of 17,105 older adults across 27 countries showing that physical inactivity, social participation, and intellectual activities have differential associations with specific cognitive domains across healthy, dementia, Parkinson's disease, and stroke groups, with…

WHY IT MATTERS

Research significance

While it provides little mechanistic or pharmacological insight for Parkinson's therapeutic discovery, the study supports targeting physical activity and cognitive engagement as adjunctive, non‑drug strategies and informs selection of cognitive endpoints and lifestyle covariates for PD clinical…

ABSTRACT

Source abstract

Background/Objectives: As life expectancy increases, chronic diseases have become more prevalent, often leading to poorer health in later years. Maintaining cognitive functioning is therefore essential for preserving independence in older adulthood. Within the framework of cognitive enrichment, research highlights the protective role of healthy lifestyles and engagement in social and intellectual activities on cognitive functioning. This study aimed to provide evidence of the moderator effect of diagnosis group (including healthy condition, dementia, Parkinson's, and stroke) on a predictive model of cognitive function. Methods: Data employed in this study came from the 9th wave of the Survey of Health, Ageing and Retirement in Europe (SHARE) project, including 17,105 individuals aged 50 years and older from 27 European countries. Cognitive functioning was assessed through numeracy, temporal orientation, verbal fluency, and memory. Physical inactivity, social participation, intellectual activities, age, gender, and education were included as predictors. A measurement invariance routine across diagnostic groups was tested. Results: The model demonstrated excellent fit in the general sample and partial invariance across groups. Physical inactivity was negatively associated with numeracy in all groups, with stronger effects in clinical populations, particularly stroke and dementia. Intellectual activities were positively associated with numeracy across groups, with the largest effects observed in dementia. Temporal orientation, physical inactivity and intellectual activities showed significant associations mainly in clinical groups, whereas age demonstrated a consistent negative effect across all groups. Conclusions: Lifestyle factors show differential associations with cognitive domains depending on diagnostic condition. These findings support the heterogeneity of cognitive aging and highlight the importance of tailored, person-centered intervention strategies.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic